A low alpha-1 antitrypsin result is a screening clue, not a genetic diagnosis. The next step is usually phenotype or genotype confirmation, followed by thoughtful—not indiscriminate—family testing.
- Protective threshold is approximately 11 µmol/L, often reported as 57 mg/dL by nephelometry; values below it raise concern for severe deficiency.
- Low AAT level alone cannot distinguish inherited deficiency from a temporary laboratory effect, liver disease, protein loss, or assay differences.
- Pi*MZ carrier status usually produces about 60% of typical AAT concentrations and matters most when combined with cigarette smoke or major occupational dust exposure.
- Pi*ZZ deficiency commonly produces AAT concentrations around 20–45 mg/dL and carries meaningful lung and liver risk.
- AAT genotype test for common S and Z variants is useful, but phenotyping or gene sequencing may be needed when the level and genotype disagree.
- Acute-phase effect can raise AAT by roughly 75% to 100% during infection, injury, pregnancy, or active inflammation and can conceal deficiency.
- Deuchainn teaghlaich is generally offered to parents, siblings, children, and partners of a confirmed carrier or affected person after genetic counselling.
- Smoking avoidance is the single most powerful lung-protection measure for people with severe AAT deficiency or an at-risk genotype.
What a low alpha-1 antitrypsin result actually means
Low alpha-1 antitrypsin levels are a clue to reduced protective protein activity, not proof that you have severe inherited deficiency. A concentration below roughly 11 µmol/L—or about 57 mg/dL on many nephelometric assays—deserves confirmatory testing because that is the traditional biochemical threshold below which lung tissue receives substantially less antiprotease protection.
Alpha-1 antitrypsin, or AAT, is made mainly in the liver and circulates to the lungs, where it counterbalances neutrophil elastase. In practical terms, too little AAT leaves alveolar tissue more vulnerable to damage over decades, especially with tobacco exposure. Liver enzymes should be read alongside it; our guide to liver test abbreviations explains why ALT, AST, bilirubin and albumin add useful context.
A laboratory reference interval is not the same as the protective threshold. Many laboratories list approximately 100–190 mg/dL, or 20–37 µmol/L, for adults, yet a result of 85 mg/dL may be only mildly low and does not automatically mean PiZZ deficiency. I have seen healthy PiMZ carriers land in this middle zone, while a person tested during pneumonia can have an apparently reassuring result because AAT behaves as an acute-phase reactant.
Dr. Thomas Klein’s clinical rule is simple: treat a low concentration as the start of a pathway. Repeat or confirm it with genotype and/or phenotype testing, check C-reactive protein when inflammation is plausible, and review lung symptoms, smoking history, liver chemistry, and family history together.
Why the threshold is assay-dependent
The often-quoted 11 µmol/L threshold converts differently across methods: roughly 57 mg/dL by nephelometry, but close to 80 mg/dL with older radial immunodiffusion calibration. The laboratory’s stated method and units should travel with every result; a bare screenshot without them can mislead even an experienced clinician.
Alpha-1 antitrypsin test ranges and the protective cutoff
Most adult AAT concentrations fall near 100–190 mg/dL, but the clinically useful question is whether the result is above or below the assay-specific protective threshold. Values below 57 mg/dL by nephelometry strongly suggest severe deficiency and should not be dismissed as a minor out-of-range flag.
AAT is usually measured in serum by immunonephelometry or immunoturbidimetry. These methods quantify protein concentration, not genetic identity, which is why a level can screen efficiently but cannot give the full answer. The distinction is similar to the difference between qualitative and quantitative testing: one result tells how much is present, while another may identify what form is present.
Results from 57–90 mg/dL often sit in the diagnostic grey zone. PiSZ, PiMZ, rare variants, and a low baseline combined with ordinary analytical variation can overlap here; the coefficient of variation for routine immunoassays is commonly several percent. A repeat sample when clinically stable is more useful than trying to infer a genotype from one borderline value.
A result above 120 mg/dL does not entirely exclude a carrier state, because inflammation can increase AAT substantially. In one clinic, I reviewed an MZ carrier whose level was 154 mg/dL during a flare of inflammatory arthritis and 103 mg/dL three months later—both technically within that laboratory’s interval, but biologically very different.
Why a low level and carrier status are not the same diagnosis
Carrier status describes inherited SERPINA1 variants, whereas an AAT level describes the protein measured in one sample on one day. A person can carry one altered allele with a near-normal result, and another can have low AAT for reasons that are not inherited deficiency.
The common normal genotype is PiMM. PiMZ generally means one M and one Z allele, often with AAT around 60% of average; PiSZ tends to produce lower levels, often around 40%; PiZZ usually produces 10%–20%. Those percentages are population averages, not personal forecasts—individual values overlap more than most laboratory reports imply.
A person with Pi*MZ is a carrier, but not every carrier develops lung or liver disease. Cigarette smoking is the major modifier for obstructive lung disease, and occupational exposure to mineral dust, fumes, or biomass smoke adds concern. The COPD Foundation guideline recommends testing all people with COPD, nonresponsive asthma, unexplained bronchiectasis, or unexplained liver disease (Sandhaus et al., 2016).
Kantesti AI ’s e Anailisiche deuchainn fala AI that places a low AAT result beside inflammatory markers, liver chemistry, and pulmonary clues rather than presenting a genetic label from a single concentration. Our biomarker guide also helps patients preserve the original units and laboratory method for their clinician.
A misconception I correct often
“Carrier” does not mean “nothing to discuss.” It means the preventive conversation changes: avoid smoking completely, address workplace exposures early, and document the result so a new respiratory clinician does not mistake genetically lower AAT for a transient laboratory anomaly.
Why AAT concentrations can be falsely reassuring or unexpectedly low
Inflammation, pregnancy, infection, and tissue injury can raise AAT enough to obscure inherited deficiency, while protein loss and serious liver dysfunction can lower it. Measuring C-reactive protein and reviewing the clinical setting prevents a surprising number of false conclusions.
AAT is an acute-phase protein and may rise by approximately 75%–100% during bacterial infection, active autoimmune disease, trauma, or late pregnancy. If CRP is elevated, a normal AAT concentration is less reassuring than it appears. This is one reason a result should be repeated at least several weeks after recovery when the history and first result do not fit.
Low albumin, nephrotic-range urinary protein loss, severe malnutrition, or advanced impairment of liver protein synthesis can reduce several serum proteins together. A low AAT plus low albumin and prolonged INR points to a different clinical problem than isolated AAT reduction; the stiùireadh pròtain serum is useful background for this pattern.
Assay interference is uncommon but real. Grossly lipaemic samples, sample mix-ups, and different manufacturer calibrations can create discordance near a decision threshold. Ask for the numerical result, units, reference range, sample date, and whether the laboratory performed reflex phenotype or genotyping—“abnormal” alone is not a clinically usable result.
When genotype, phenotype, or sequencing should confirm the result
An AAT genotype test identifies common inherited variants, phenotype testing identifies circulating protein patterns, and sequencing resolves unusual or discordant cases. For a low level, clinicians commonly use at least two of these approaches rather than relying on concentration alone.
Targeted genotyping usually looks first for the S agus Z SERPINA1 alleles. It is fast and useful, but it can miss null alleles and many rare variants; a “negative for S and Z” result is not equivalent to “no inherited deficiency” if AAT is clearly low. The 2003 ATS/ERS statement specifically supports genotyping plus AAT measurement, with further testing where findings conflict (ATS/ERS, 2003).
Phenotyping uses isoelectric focusing to show the mobility pattern of AAT protein. It can identify M, S, Z and several other protein variants, but null alleles make no protein and can be missed by phenotype alone. Sequencing is particularly valuable when a very low level conflicts with MM-like phenotype or common-variant genotyping.
When I review a panel with AAT of 38 mg/dL and only one Z allele reported, I do not call it “just MZ.” I ask whether there may be a second rare or null allele. Liver assessment often follows, including a FIB-4 calculation from age, AST, ALT, and platelets, although FIB-4 has not been validated as a stand-alone AATD diagnostic tool.
How genotype changes lung risk—and why smoke changes it more
PiZZ and null genotypes confer the highest emphysema risk, while PiMZ mainly increases vulnerability in people who smoke. AAT-related emphysema often has basal-predominant panacinar features, but imaging pattern alone cannot diagnose the genotype.
Severe AAT deficiency can present with breathlessness, wheeze, chronic cough, recurrent chest infections, or reduced exercise tolerance—sometimes before age 45, although later presentation is common. Spirometry may show obstruction, but a normal spirometry result does not rule out early disease. Baseline spirometry with bronchodilator testing and diffusion capacity is generally reasonable after confirmed severe deficiency.
Smoking accelerates decline far more than genotype alone predicts. In my experience, the most preventable tragedy is a person who learns of Pi*ZZ status only after years of smoking because no one tested them when “asthma” was not behaving like asthma. Strnad and colleagues describe AAT deficiency as a lung-and-liver disorder with highly variable expression, shaped by exposure and genotype (Strnad et al., 2020).
A chest CT is not a routine screening test for every carrier. It is considered when symptoms, spirometry, diffusion capacity, or a diagnostic question justify radiation exposure; patients with breathlessness can also use our stiùireadh deuchainn-fala airson giorrad analach to understand the non-genetic causes clinicians usually check first.
Liver risk: why the blood level does not predict it perfectly
Liver injury in AAT deficiency results from retained abnormal Z protein inside hepatocytes, so a lower serum AAT level does not neatly equal higher liver risk. PiZZ carries the clearest inherited risk, while PiMZ can modify risk from alcohol, obesity, viral hepatitis, or metabolic liver disease.
Adults with confirmed severe deficiency generally need periodic liver-focused review: ALT, AST, alkaline phosphatase, GGT, bilirubin, albumin, platelet count, and an examination for hepatomegaly or splenomegaly. Normal liver enzymes do not exclude fibrosis, and a single mildly elevated ALT is nonspecific. The useful question is whether abnormalities persist or form a cholestatic, hepatocellular, or synthetic-function pattern.
Pi*MZ is increasingly recognized as a risk modifier rather than an automatic liver-disease diagnosis. The combination that concerns me is MZ plus metabolic dysfunction-associated steatotic liver disease, persistently raised ALT, declining platelets, or alcohol exposure—not MZ alone. Read more about MASLD laboratory assessment if metabolic risk is part of the picture.
Urgent assessment is warranted for jaundice, new abdominal swelling, vomiting blood, confusion, black stools, or rapidly worsening itch with dark urine. For slower changes, trend data matter: repeated values over 6–12 months can show a trajectory that one “normal” panel cannot.
Which relatives may benefit from alpha-1 antitrypsin testing
Parents, siblings, children, and the reproductive partner of a person with a confirmed abnormal SERPINA1 genotype should be offered genetic counselling and testing. Testing relatives by AAT level alone is less reliable than family-based genotype testing because carrier levels overlap the reference interval.
A confirmed PiZZ result means each parent is usually at least a carrier, and each child inherits one altered allele. A PiMZ result means first-degree relatives may carry MZ, ZZ, or other combinations depending on the other parent’s genotype. Family testing is about informed prevention and reproductive clarity, not assigning blame; genes do not follow family hierarchies or good intentions.
The COPD Foundation guideline recommends offering testing to adult siblings, parents, children, and extended family after identifying an abnormal gene, with counselling before and after testing (Sandhaus et al., 2016). Children can be considered when the result will affect medical care or household smoke exposure, ideally through a paediatric clinician or genetics professional who understands the family’s context.
Kantesti AI supports family risk conversations by organizing separate, consented laboratory histories rather than assuming one relative’s data belongs to another. Our family health-record guide explains the practical details worth saving: exact genotype, assay method, baseline lung testing, liver trends, and exposures.
How to discuss inherited AAT risk without creating unnecessary alarm
The clearest family message is: a confirmed result can affect prevention, but it does not predict that every relative will become ill. Share the exact genotype and laboratory report, avoid guessing from symptoms, and offer a route to genetic counselling.
Start with a short factual note: “I have confirmed SERPINA1 genotype X; my clinician advised close relatives to consider testing.” Include the laboratory name and date, but do not photograph another person’s medical portal without permission. A 10-minute phone call is often kinder than a cryptic group message announcing a “genetic lung disease.”
Relatives may reasonably ask about employment, insurance, stigma, and reproductive decisions. Those answers vary by country, so a local genetics counsellor is more useful than social-media reassurance. The multi-patient health management guide outlines consent-based ways to keep family results separate while retaining an accurate inheritance record.
Dr. Thomas Klein advises against testing distant relatives in a cascade without first clarifying the affected person’s genotype. If the first person only has a low AAT concentration and no confirmatory test, the family may be chasing an ambiguous biochemical result rather than a defined inherited variant.
A practical next-step plan after a low AAT result
After a low AAT result, confirm the assay and units, assess inflammation, order genotype or phenotype testing, and review lung and liver status. Most people do not need emergency treatment, but confirmed severe deficiency should lead to structured follow-up rather than a forgotten chart note.
Step one is verification: obtain the actual result and determine whether it was serum or plasma, nephelometry or another method, and whether CRP was raised. Step two is confirmation with S/Z genotyping plus phenotype, or sequencing when the phenotype, genotype, and level do not line up. This sequence is more informative than repeating random AAT levels every few weeks.
Step three is baseline assessment tailored to the result. Confirmed severe deficiency commonly prompts spirometry, bronchodilator response, diffusion capacity where available, liver chemistry, platelet count, and counselling on smoke, vaping, biomass exposure, and workplace irritants. Vaccinations and routine respiratory care remain sensible, but there is no supplement that replaces missing AAT.
Kantesti AI ’s e seirbheis eadar-mhìneachaidh deuchainn-lann AI that can help organize the original AAT result, CRP, liver panel, and serial values before a medical appointment; it does not replace diagnostic confirmation by a laboratory and clinician. Before sharing any report, review our PDF upload privacy checklist and remove identifiers you do not need to retain.
When augmentation therapy is considered—and when it is not
Intravenous AAT augmentation therapy is generally considered for confirmed severe deficiency with established airflow obstruction, not for isolated low levels or most carriers. The usual licensed regimen in many settings is 60 mg/kg intravenously once weekly, although national eligibility and funding rules differ.
Augmentation increases circulating AAT and has evidence for slowing loss of lung density on CT in selected people with severe AATD-related emphysema. It does not reverse existing emphysema, treat liver disease, or substitute for smoking cessation. Decisions typically involve a respiratory specialist, documented genotype, serum level, spirometry, CT context, and local criteria.
Pi*MZ carriers are not routinely treated with augmentation therapy, even if their AAT concentration is slightly low. That distinction matters because treatment burden is substantial: weekly infusions, venous access logistics, cost, and occasional infusion reactions. The most effective intervention for an MZ smoker remains complete cessation, not chasing a protein level.
Some patients ask whether exercise is unsafe. Usually, no: supervised aerobic and strength work are helpful when adjusted to symptoms, oxygenation, and pulmonary rehabilitation advice. If a clinician proposes augmentation, ask what outcome they are targeting and how they will measure benefit over the next 12 months.
Special situations: pregnancy, children, and unexplained respiratory disease
Pregnancy and active inflammation can elevate AAT and obscure deficiency, while children with confirmed family variants need age-appropriate counselling rather than automatic disease labeling. Unexplained bronchiectasis, persistent obstruction, or liver disease at any age can justify an alpha-1 antitrypsin deficiency test.
During pregnancy, AAT often rises as part of the normal acute-phase response, so a normal concentration cannot reliably exclude carrier status in a known affected family. Genotype does not change with pregnancy and can be performed at any time. Prenatal or reproductive testing should be discussed with genetics professionals because the value lies in informed choice, not urgent medical treatment.
For children, the immediate benefits of knowing a confirmed familial variant may include a smoke-free home, avoidance of future tobacco use, and appropriate evaluation of persistent liver abnormalities. The potential downsides include anxiety and future privacy concerns, so the timing should be individualized. A normal newborn screen does not generally answer this question unless it included validated SERPINA1 testing.
AAT deficiency is commonly missed in people labelled with poorly responsive asthma. If wheeze began in adulthood, airflow obstruction is fixed, or CT suggests lower-lung emphysema, ask whether AAT was ever checked; recurrent respiratory infections may also warrant the broader frequent-infection blood-test workup.
Using AI interpretation safely for an inherited protein result
AI can organize an AAT result and flag the need for confirmation, but it cannot determine a rare SERPINA1 genotype from a protein concentration. Safe interpretation preserves units, reference intervals, medication and illness context, and clearly separates risk screening from diagnosis.
Kantesti AI ’s e Inneal mion-sgrùdaidh deuchainn fala le cumhachd AI that reviews an alpha-1 antitrypsin test alongside CRP, albumin, bilirubin, AST, ALT, platelets, and prior results in approximately 60 seconds. A sensible output should say “consider confirmation” for a low level, not tell a patient they have Pi*ZZ without genotype or phenotype evidence.
Trend analysis is especially useful after an acute illness. AAT of 112 mg/dL with CRP 68 mg/L may be less reassuring than 92 mg/dL with CRP below 3 mg/L, yet neither value determines genotype. We designed our interpretation logic to flag this discordance for clinician discussion; readers can review the relevant clinical safeguards in our geàrr-shealladh dearbhaidh meidigeach.
As of September 26, 2026, Dr. Thomas Klein still recommends specialist input for a confirmed severe result, unexplained obstructive lung disease, abnormal liver tests, or a genotype-level family decision. AI should shorten the route to that conversation, not replace it.
Questions to take to your clinician after AAT testing
The most useful questions ask whether your concentration, phenotype, and genotype agree, and whether your lungs or liver show any current effect. Bring the complete report rather than relying on a portal flag or a recollection of the number.
Ask: “What method measured my AAT, what is the value in mg/dL and µmol/L, and was CRP elevated?” Then ask: “Do I need S/Z genotyping, phenotype testing, or full sequencing?” These questions prevent the common dead end of being told simply that a result is “a little low.”
If severe deficiency is confirmed, ask about baseline spirometry, diffusion capacity, vaccinations, workplace exposure, liver monitoring, and whether a respiratory or liver specialist should coordinate care. If you are a carrier, ask for a plain-language explanation of your personal risk rather than a binary “normal/abnormal” label. The family doctor result-sharing guide may help you prepare a concise record for that visit.
Our medical content is reviewed with physician oversight, and the Bòrd Comhairleachaidh Meidigeach explains how clinical expertise informs Kantesti AI’s educational boundaries. The practical goal is not to turn every low result into a diagnosis; it is to make sure a significant inherited deficiency is not missed.
Bottom line for low AAT levels and family risk
A low AAT concentration should lead to confirmation, not panic: genotype and phenotype testing clarify whether the finding is severe deficiency, carrier status, a rare variant, or a non-genetic effect. Once a familial variant is confirmed, first-degree relatives can make informed decisions about testing and prevention.
The number that changes urgency is an assay-specific value near or below 11 µmol/L, often 57 mg/dL by nephelometry. Below that level, severe deficiency or null variants become much more plausible; above it, carriers and inflammatory masking still require context. The result belongs with CRP, genotype, phenotype, exposure history, and organ assessment.
Most patients find the family conversation becomes manageable once they have one accurate sentence to share: “This is inherited, testing is available, and the result may help protect lungs by preventing smoke exposure.” That is a more useful message than asking relatives to diagnose themselves from cough, fatigue, or an online calculator.
Kantesti AI can retain longitudinal laboratory context across visits, while the iùl teicneòlais airson mìneachadh AI describes why source values and uncertainty are preserved. Confirmed AAT deficiency deserves medical follow-up; a single low result deserves careful interpretation first.
Ceistean Bitheanta
Dè an ìre de dh’alpha-1 antitrypsin a thathas a’ meas ìosal?
Tha dùmhlachd alpha-1 antitrypsin fo mu 11 µmol/L air a mheas fo stairs dìon traidiseanta airson clò nan sgamhan. Air mòran deuchainnean nephelometric, tha 11 µmol/L a' freagairt ri mu 57 mg/dL, ach faodaidh seann dhòighean dìoladh dìonach radial aithris air stairs coltach nas fhaisge air 80 mg/dL. Tha mòran de raointean iomraidh inbheach mu 100–190 mg/dL, ged a shocraicheas gach obair-lann an raon aice fhèin. Bu chòir toradh ìosal a dhearbhadh le deuchainn genotype agus/no phenotype oir chan eil dùmhlachd leis fhèin a' stèidheachadh an caochladh oighreachail.
An urrainn dhut ìrean àbhaisteach de alpha-1 antitrypsin a bhith agad agus fhathast a bhith nad neach-giùlain?
Seadh, faodaidh neach ìre àbhaisteach alpha-1 antitrypsin a bhith aige agus fhathast cèidse caochladh SERPINA1 a bhith aige, gu sònraichte Pi*MZ. Faodaidh sèid dian, galar, torrachas, agus leòn AAT àrdachadh timcheall air 75% gu 100%, a dh’ fhaodas cinneasachadh bunaiteach a tha nas ìsle air sgàth ginteil fhalach. Tha ginteachadh targaid airson caochlaidhean S agus Z no phenotyping pròtain nas earbsaiche na ìre a-mhàin airson dearbhadh inbhe cèidse. Tha seo gu sònraichte buntainneach nuair a tha càirdeas dlùth air dearbhadh gu bheil dìth AAT orra.
A bheil Pi*MZ a' ciallachadh gum faigh thu emphysema?
PiMZ does not mean that emphysema is inevitable. PiMZ commonly produces about 60% of average AAT concentration, and many nonsmokers never develop clinically significant lung disease. Cigarette smoke is the strongest known modifiable risk factor, while workplace dust, fumes, and biomass smoke can add risk. A Pi*MZ result is most useful as a reason to avoid tobacco completely and to investigate persistent respiratory symptoms appropriately.
Should children of someone with alpha-1 antitrypsin deficiency be tested?
Children of a person with a confirmed abnormal SERPINA1 genotype may benefit from testing, but the timing should be individualized with a paediatric clinician or genetics professional. The result can support a permanently smoke-free home and clarify evaluation of persistent liver abnormalities, yet it may also create anxiety and privacy concerns. Genotype testing is not affected by age, while AAT concentration can vary with inflammation. A confirmed family genotype makes the discussion much clearer than an isolated low protein result in one adult.
What is the difference between AAT phenotype and genotype testing?
AAT phenotype testing uses protein separation, usually isoelectric focusing, to identify the pattern of AAT proteins circulating in serum. AAT genotype testing examines the SERPINA1 gene, commonly starting with S and Z variants. Phenotyping can miss null variants because they produce no detectable protein, while limited genotyping can miss rare variants not included in the panel. When AAT is very low or the level and first genetic result disagree, sequencing may be the most definitive next test.
Can alpha-1 antitrypsin deficiency affect the liver even when lung tests are normal?
Yes, alpha-1 antitrypsin deficiency can affect the liver independently of lung function. In Pi*ZZ disease, abnormal Z protein can accumulate within hepatocytes, while low circulating AAT chiefly explains lung vulnerability. ALT, AST, GGT, bilirubin, albumin, platelet count, and sometimes liver imaging or elastography are used to assess liver status. Normal spirometry does not rule out liver involvement, and normal liver enzymes do not completely rule out fibrosis.
Faigh Mion-sgrùdadh Deuchainn Fala le Cumhachd AI an-diugh
Thig còmhla ri còrr is 2 mhillean neach air feadh an t-saoghail a tha a’ earbsa Kantesti airson mion-sgrùdadh sa bhad, ceart air deuchainnean obair-lann. Luchdaich suas na toraidhean deuchainn fala agad agus faigh mìneachadh coileanta air biomarcair 15,000+ ann an diogan.
📚 Foillseachaidhean Rannsachaidh le Iomraidhean
Klein, T., Mitchell, S., & Weber, H. (2026). Klein, T. (2026). aPTT Normal Range: D-Dimer, Protein C Blood Clotting Guide. Zenodo. https://doi.org/10.5281/zenodo.18262555. ResearchGate: https://www.researchgate.net/. Academia.edu: https://www.academia.edu/.. Rannsachadh Leigheis AI Kantesti.
Klein, T., Mitchell, S., & Weber, H. (2026). Klein, T. (2026). Serum Proteins Guide: Globulins, Albumin & A/G Ratio Blood Test. Zenodo. https://doi.org/10.5281/zenodo.18316300. ResearchGate: https://www.researchgate.net/. Academia.edu: https://www.academia.edu/.. Rannsachadh Leigheis AI Kantesti.
📖 Iomraidhean Meidigeach Taobh a-muigh
⚕️ Àicheadh Meidigeach
Tha an artaigil seo dìreach airson adhbharan foghlaim agus chan eil e a’ dèanamh comhairle mheidigeach. Cuir fios an-còmhnaidh gu solaraiche cùram slàinte teisteanasach airson co-dhùnaidhean breithneachaidh is leigheis.
Comharran earbsa E-E-A-T
Eòlas
Lèirmheas clionaigeach air a stiùireadh le lighiche air sruthan-obrach mìneachaidh obair-lann.
Eòlas
Fòcas air leigheas obair-lann air mar a bhios bith-chomharraidhean (biomarkers) a’ giùlan ann an co-theacsa clionaigeach.
Ùghdarrasachd
Air a sgrìobhadh le Dr. Thomas Klein le ath-sgrùdadh le Dr. Sarah Mitchell agus Prof. Dr. Hans Weber.
Earbsachd
Mìneachadh stèidhichte air fianais le slighean leanmhainn soilleir gus dragh a lughdachadh.